Are Patients With High-Risk Polycythemia Vera Receiving Cytoreductive Medications? A Retrospective Analysis of Real-World Data

A retrospective analysis found that only 42.0% and 18.9% of patients with high-risk and low-risk polycythemia vera, respectively, received cytoreductive therapy overall, despite guidelines recommending the treatment as part of risk-adapted therapy.

 Experimental Hematology & Oncology

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.